Neurogene Inc. (NGNE) stock
NGNENasdaqPharmaceutical PreparationsFiscal year ends December 31
$22.15−0.78 (-3.40%)
Close on Nov 20, 2026Market cap $443.25MP/E –Yield –
Neurogene shares outstanding
Diluted shares outstanding: the weighted share count used for earnings per share, adjusted for stock splits.
Neurogene's shares outstanding was 23M at Jun 30, 2026. For fiscal 2025 it was 21M, up 21.4% from the year before. Over ten years it grew 28.5% a year on average. The highest annual figure on record is 21M in fiscal 2025.
Annual shares outstanding
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 21M | +21.4% |
| FY2024 | Dec 31, 2024 | 18M | +59.1% |
| FY2022 | Dec 31, 2022 | 11M | +0.3% |
| FY2021 | Dec 31, 2021 | 11M | +6.2% |
| FY2020 | Dec 31, 2020 | 10M | +91.7% |
| FY2019 | Dec 31, 2019 | 5M | +14.9% |
| FY2018 | Dec 31, 2018 | 5M | +0.3% |
| FY2017 | Dec 31, 2017 | 5M | +24.1% |
| FY2016 | Dec 31, 2016 | 4M | +49.5% |
| FY2015 | Dec 31, 2015 | 3M | +45.8% |
| FY2014 | Dec 31, 2014 | 2M | +2772.4% |
| FY2013 | Dec 31, 2013 | 0M | 0.0% |
| FY2012 | Dec 31, 2012 | 0M | – |
Quarterly shares outstanding
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 23M | +7.1% |
| Q1 FY2026 | Mar 31, 2026 | 22M | +6.2% |
| Q4 FY2025 | Dec 31, 2025 | 22M | +13.4% |
| Q3 FY2025 | Sep 30, 2025 | 21M | +24.9% |
| Q2 FY2025 | Jun 30, 2025 | 21M | +24.3% |
| Q1 FY2025 | Mar 31, 2025 | 21M | +24.2% |
| Q4 FY2024 | Dec 31, 2024 | 19M | +4262.8% |
| Q3 FY2024 | Sep 30, 2024 | 17M | +3714.3% |
| Q2 FY2024 | Jun 30, 2024 | 17M | +52.8% |
| Q1 FY2024 | Mar 31, 2024 | 17M | +52.9% |
| Q3 FY2023 | Sep 30, 2023 | 0M | -96.0% |
| Q2 FY2023 | Jun 30, 2023 | 0M | -96.0% |
| Q1 FY2023 | Mar 31, 2023 | 11M | +0.5% |
| Q4 FY2022 | Dec 31, 2022 | 11M | +0.3% |
| Q3 FY2022 | Sep 30, 2022 | 11M | +0.3% |
| Q2 FY2022 | Jun 30, 2022 | 11M | +0.3% |
| Q1 FY2022 | Mar 31, 2022 | 11M | +0.4% |
| Q4 FY2021 | Dec 31, 2021 | 11M | +0.9% |
| Q3 FY2021 | Sep 30, 2021 | 11M | +1.8% |
| Q2 FY2021 | Jun 30, 2021 | 11M | +11.4% |
| Q1 FY2021 | Mar 31, 2021 | 11M | +11.7% |
| Q4 FY2020 | Dec 31, 2020 | 11M | +56.8% |
| Q3 FY2020 | Sep 30, 2020 | 11M | +106.7% |
| Q2 FY2020 | Jun 30, 2020 | 10M | +109.8% |
| Q1 FY2020 | Mar 31, 2020 | 10M | +108.9% |
| Q4 FY2019 | Dec 31, 2019 | 7M | +48.0% |
| Q3 FY2019 | Sep 30, 2019 | 5M | +11.3% |
| Q2 FY2019 | Jun 30, 2019 | 5M | -1.3% |
| Q1 FY2019 | Mar 31, 2019 | 5M | +0.2% |
| Q4 FY2018 | Dec 31, 2018 | 5M | +0.3% |
| Q3 FY2018 | Sep 30, 2018 | 5M | +0.3% |
| Q2 FY2018 | Jun 30, 2018 | 5M | +1.7% |
| Q1 FY2018 | Mar 31, 2018 | 5M | -99.9% |
| Q4 FY2017 | Dec 31, 2017 | 5M | +0.1% |
| Q3 FY2017 | Sep 30, 2017 | 5M | +32.6% |
| Q2 FY2017 | Jun 30, 2017 | 5M | – |
| Q1 FY2017 | Mar 31, 2017 | 4.68B | – |
| Q4 FY2016 | Dec 31, 2016 | 5M | – |
| Q3 FY2016 | Sep 30, 2016 | 4M | – |
See a number that looks wrong?